NEW YORK (GenomeWeb News) – BG Medicine today reported a 175 percent increase year over year in revenues for the fourth quarter as product revenues increased more than three-fold.

The Waltham, Mass.-based firm said that revenues for the three months ended Dec. 31, 2012 totaled $1.1 million, up from $379,000 a year ago and beating the average analyst estimate of $940,000. Product revenues increased to $978,000 from $307,000 a year ago, and service revenues rose to $94,000 from $72,000, a 31 percent jump.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.